Bristol Myers Squibb (BMY) EBIT Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 7.73% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 33.03% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -15.60% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 44.54% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 53.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.03% |
| Mar 31, 2026 | -42.48% |
| Dec 31, 2025 | -52.96% |
| Sep 30, 2025 | -30.63% |
| Jun 30, 2025 | -28.03% |
| Mar 31, 2025 | 57.08% |
| Dec 31, 2024 | -110.38% |
| Sep 30, 2024 | -112.23% |
| Jun 30, 2024 | -30.13% |
| Mar 31, 2024 | -259.49% |
| Dec 31, 2023 | 56.88% |
| Sep 30, 2023 | -14.63% |
| Jun 30, 2023 | 1.74% |
| Mar 31, 2023 | 27.06% |
| Dec 31, 2022 | 34.58% |
| Sep 30, 2022 | 31.14% |
| Jun 30, 2022 | -57.24% |
| Mar 31, 2022 | -91.82% |
| Dec 31, 2021 | -68.01% |
| Sep 30, 2021 | -31.20% |